Pharmacokinetic Optimisation in the Treatment of Parkinson???s Disease
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 45 (2) , 109-136
- https://doi.org/10.2165/00003088-200645020-00001
Abstract
Pharmacotherapy for Parkinson’s disease is focused on dopaminergic drugs, mainly the dopamine precursor levodopa and dopamine receptor agonists. The elimination half-life (t½) of levodopa from plasma...Keywords
This publication has 121 references indexed in Scilit:
- RasagilineDrugs & Aging, 2005
- Tolcapone-Related Liver DysfunctionDrug Safety, 2003
- Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson??s DiseaseClinical Pharmacokinetics, 2002
- Pharmacokinetic-Pharmacodynamic Relationship of Levodopa with and without Tolcapone in Patients with Parkinson??s DiseaseClinical Pharmacokinetics, 2001
- Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson??s DiseaseCNS Drugs, 2000
- Chronic levodopa therapy enhances dopa absorption: Contribution to wearing-offJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1996
- Clinical Pharmacokinetics of Amantadine HydrochlorideClinical Pharmacokinetics, 1988
- Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 1987
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984
- Clinical Pharmacokinetics of Levodopa in Parkinson??s DiseaseClinical Pharmacokinetics, 1976